Theranostics 2020; 10(10):4544-4556. doi:10.7150/thno.40532 This issue Cite

Review

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Jicheng Wu1,2*, Shen Hu3*, Lihong Zhang4, Jinxia Xin1,2, Chongran Sun5, Liquan Wang3✉, Kefeng Ding1✉, Ben Wang1,2✉

1. Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
2. Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China
3. Department of Obstetrics, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
4. Department of Biochemistry, College of Biomedical Sciences, Zhejiang University School of Medicine, Hangzhou 310009, China
5. Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
* These authors contributed equally to this work.

Citation:
Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L, Ding K, Wang B. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics 2020; 10(10):4544-4556. doi:10.7150/thno.40532. https://www.thno.org/v10p4544.htm
Other styles

File import instruction

Abstract

Graphic abstract

Liquid biopsy is a convenient, fast, non-invasive and reproducible sampling method that can dynamically reflect the changes in tumor gene expression profile, and provide a robust basis for individualized therapy and early diagnosis of cancer. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are the currently approved diagnostic biomarkers for screening cancer patients. In addition, tumor-derived extracellular vesicles (tdEVs), circulating tumor-derived proteins, circulating tumor RNA (ctRNA) and tumor-bearing platelets (TEPs) are other components of liquid biopsies with diagnostic potential. In this review, we have discussed the clinical applications of these biomarkers, and the factors that limit their implementation in routine clinical practice. In addition, the most recent developments in the isolation and analysis of circulating tumor biomarkers have been summarized, and the potential of non-blood liquid biopsies in tumor diagnostics has also been discussed.

Keywords: liquid biopsy, tumor circulome, tumor screening


Citation styles

APA
Wu, J., Hu, S., Zhang, L., Xin, J., Sun, C., Wang, L., Ding, K., Wang, B. (2020). Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics, 10(10), 4544-4556. https://doi.org/10.7150/thno.40532.

ACS
Wu, J.; Hu, S.; Zhang, L.; Xin, J.; Sun, C.; Wang, L.; Ding, K.; Wang, B. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics 2020, 10 (10), 4544-4556. DOI: 10.7150/thno.40532.

NLM
Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L, Ding K, Wang B. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics 2020; 10(10):4544-4556. doi:10.7150/thno.40532. https://www.thno.org/v10p4544.htm

CSE
Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L, Ding K, Wang B. 2020. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics. 10(10):4544-4556.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image